SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites ...

SAB BIO to Participate in Upcoming Investor Conferences

SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte ...

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Details of the novel pharmacokinetic assay for measuring SAB-142.
Nasdaq

SAB BIO Reports Positive Phase 1 Trial Results for SAB-142 in Type 1 Diabetes, Supporting Advancement to Phase 2b Development

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Railway Technology

Industry 4.0 Automated Production Cables and Wires from SAB

Industry 4.0 is the new focus of German manufacturing. Adaptable, efficient and digital, it links and communicates all stages of the production process. This can result in significant improvements in ...